COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY

Objective: To compare efficacy of 3 commonly prescribed anti-depressants from classes’ selective serotonin reuptake inhibitor and serotonin-nor epinephrine reuptake inhibitors i.e. Venlafaxine, Duloxetine and Sertraline in the management of diabetic sensory neuropathy in subjects with type 2 diabete...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nabila Shaukat, Shazia Nisar, Usman Sajid, Osman Ali Jan, Amjad Mahmood, Huma Zahid
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	diabetes mellitus diabetic sensory neuropathy duloxetine venlafaxine sertraline Medicine R Medicine (General) R5-920
Acceso en línea:	https://doi.org/10.51253/pafmj.v71i1.4780 https://doaj.org/article/30881a97cf374b71a42c077c1b8533aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:30881a97cf374b71a42c077c1b8533aa
record_format	dspace
spelling	oai:doaj.org-article:30881a97cf374b71a42c077c1b8533aa2021-12-02T15:11:35ZCOMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHYhttps://doi.org/10.51253/pafmj.v71i1.47800030-96482411-8842https://doaj.org/article/30881a97cf374b71a42c077c1b8533aa2021-02-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/4780https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To compare efficacy of 3 commonly prescribed anti-depressants from classes’ selective serotonin reuptake inhibitor and serotonin-nor epinephrine reuptake inhibitors i.e. Venlafaxine, Duloxetine and Sertraline in the management of diabetic sensory neuropathy in subjects with type 2 diabetes mellitus. Study Design: Comparative, prospective study. Place and Duration of Study: Combined Military Hospital Jhelum, Mar 2018 to Jul 2018. Methodology: This study included 94 patients with metabolically stable type 2 Diabetes Mellitus with diabetic sensory neuropathy. Patients were randomly assigned into 3 treatment group, treatment group 1 (n1=29) recei-ving Venlafaxine 37.5mg × BD, treatment group 2 (n2=33) receiving duloxetine 30mg × BD and treatment group 3 (n3=25) receiving Sertraline 50mg × OD, each group being treated for 6 weeks, with optional dose titration fortnightly. The efficacy measure was done by revised Neuropathy Disability Score (NDS), measured at baseline and at the end of treatment period i.e. 6 weeks. The primary outcome of this study was “functional outcome” assessed by Disability Neuropathy scale (DNS) and overall improvement and adverse events were measured as secondary outcome measures. Results: There was significant improvement in Neuropathy Disability scale (DNS) at the end of treatment period in all treatment groups from their baseline score, with comparable efficacy among all drug groups i.e. p-value between venlafaxine and duloxetine, venlafaxine and sertraline were non-significant i.e. p>0.05 except between Duloxetine and Sertraline group where there was significant difference in efficacy (p<0.05). Good, moderate and mild improvement in symptoms was noticed in all study groups. Conclusion: Non-tricyclic Anti-depressants i.e. Venlafaxine, Duloxetine and Sertraline demonstrate comparable efficacy, safety and tolerability in managing Diabetic sensory neuropathy.Nabila ShaukatShazia NisarUsman SajidOsman Ali JanAmjad MahmoodHuma ZahidArmy Medical College Rawalpindiarticlediabetes mellitusdiabetic sensory neuropathyduloxetinevenlafaxinesertralineMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 1, Pp 228-233 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes mellitus diabetic sensory neuropathy duloxetine venlafaxine sertraline Medicine R Medicine (General) R5-920
spellingShingle	diabetes mellitus diabetic sensory neuropathy duloxetine venlafaxine sertraline Medicine R Medicine (General) R5-920 Nabila Shaukat Shazia Nisar Usman Sajid Osman Ali Jan Amjad Mahmood Huma Zahid COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY
description	Objective: To compare efficacy of 3 commonly prescribed anti-depressants from classes’ selective serotonin reuptake inhibitor and serotonin-nor epinephrine reuptake inhibitors i.e. Venlafaxine, Duloxetine and Sertraline in the management of diabetic sensory neuropathy in subjects with type 2 diabetes mellitus. Study Design: Comparative, prospective study. Place and Duration of Study: Combined Military Hospital Jhelum, Mar 2018 to Jul 2018. Methodology: This study included 94 patients with metabolically stable type 2 Diabetes Mellitus with diabetic sensory neuropathy. Patients were randomly assigned into 3 treatment group, treatment group 1 (n1=29) recei-ving Venlafaxine 37.5mg × BD, treatment group 2 (n2=33) receiving duloxetine 30mg × BD and treatment group 3 (n3=25) receiving Sertraline 50mg × OD, each group being treated for 6 weeks, with optional dose titration fortnightly. The efficacy measure was done by revised Neuropathy Disability Score (NDS), measured at baseline and at the end of treatment period i.e. 6 weeks. The primary outcome of this study was “functional outcome” assessed by Disability Neuropathy scale (DNS) and overall improvement and adverse events were measured as secondary outcome measures. Results: There was significant improvement in Neuropathy Disability scale (DNS) at the end of treatment period in all treatment groups from their baseline score, with comparable efficacy among all drug groups i.e. p-value between venlafaxine and duloxetine, venlafaxine and sertraline were non-significant i.e. p>0.05 except between Duloxetine and Sertraline group where there was significant difference in efficacy (p<0.05). Good, moderate and mild improvement in symptoms was noticed in all study groups. Conclusion: Non-tricyclic Anti-depressants i.e. Venlafaxine, Duloxetine and Sertraline demonstrate comparable efficacy, safety and tolerability in managing Diabetic sensory neuropathy.
format	article
author	Nabila Shaukat Shazia Nisar Usman Sajid Osman Ali Jan Amjad Mahmood Huma Zahid
author_facet	Nabila Shaukat Shazia Nisar Usman Sajid Osman Ali Jan Amjad Mahmood Huma Zahid
author_sort	Nabila Shaukat
title	COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY
title_short	COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY
title_full	COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY
title_fullStr	COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY
title_full_unstemmed	COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY
title_sort	comparative study of effectiveness of venlafaxine, duloxetine and sertraline in management of diabetic sensory neuropathy
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doi.org/10.51253/pafmj.v71i1.4780 https://doaj.org/article/30881a97cf374b71a42c077c1b8533aa
work_keys_str_mv	AT nabilashaukat comparativestudyofeffectivenessofvenlafaxineduloxetineandsertralineinmanagementofdiabeticsensoryneuropathy AT shazianisar comparativestudyofeffectivenessofvenlafaxineduloxetineandsertralineinmanagementofdiabeticsensoryneuropathy AT usmansajid comparativestudyofeffectivenessofvenlafaxineduloxetineandsertralineinmanagementofdiabeticsensoryneuropathy AT osmanalijan comparativestudyofeffectivenessofvenlafaxineduloxetineandsertralineinmanagementofdiabeticsensoryneuropathy AT amjadmahmood comparativestudyofeffectivenessofvenlafaxineduloxetineandsertralineinmanagementofdiabeticsensoryneuropathy AT humazahid comparativestudyofeffectivenessofvenlafaxineduloxetineandsertralineinmanagementofdiabeticsensoryneuropathy
_version_	1718387620876124160

COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY

Ejemplares similares